CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

BLA FilingJemperliPositive
AI Analysis

Summary

GSK's supplemental BLA for Jemperli in rectal cancer has received FDA Priority review designation, expediting the regulatory review process.

Outcome Details

sBLA received FDA Priority review designation

Importance:7/10
Sentiment:
0.70
FDA Priority ReviewsBLAoncologyregulatory approval
Related Companies

Read the original article

Published by yahoo_finance on August 24, 2026 3:37 PM

Read Original